Hyperpolarized ¹³C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring

Abstract

Metabolic imaging of brain tumors using ¹³C Magnetic Resonance Spectroscopy (MRS) of hyperpolarized [1- ¹³C] pyruvate is a promising neuroimaging strategy which, after a decade of preclinical success in glioblastoma (GBM) models, is now entering clinical trials in multiple centers. Typically, the presence of GBM has been associated with elevated hyperpolarized [1- ¹³C] lactate produced from [1- ¹³C] pyruvate, and response to therapy has been associated with a drop in hyperpolarized [1- ¹³C] lactate. However, to date, lower grade gliomas had not been investigated using this approach. The most prevalent mutation in lower grade gliomas is the isocitrate dehydrogenase 1 (IDH1) mutation, which, in addition to initiating tumor development, also induces metabolic reprogramming. In particular, mutant IDH1 gliomas are associated with low levels of lactate dehydrogenase A (LDHA) and monocarboxylate transporters 1 and 4 (MCT1, MCT4), three proteins involved in pyruvate metabolism to lactate. We therefore investigated the potential of ¹³C MRS of hyperpolarized [1- ¹³C] pyruvate for detection of mutant IDH1 gliomas and for monitoring of their therapeutic response. We studied patient-derived mutant IDH1 glioma cells that underexpress LDHA, MCT1 and MCT4, and wild-type IDH1 GBM cells that express high levels of these proteins. Mutant IDH1 cells and tumors produced significantly less hyperpolarized [1- ¹³C] lactate compared to GBM, consistent with their metabolic reprogramming. Furthermore, hyperpolarized [1- ¹³C] lactate production was not affected by chemotherapeutic treatment with temozolomide (TMZ) in mutant IDH1 tumors, in contrast to previous reports in GBM. Our results demonstrate the unusual metabolic imaging profile of mutant IDH1 gliomas, which, when combined with other clinically available imaging methods, could be used to detect the presence of the IDH1 mutation in vivo.

Graphical abstract

Highlights

• •

  Metabolic imaging of mutant IDH1 gliomas using hyperpolarized ¹³C MRS is described.

• •

  In contrast to GBM, mutant IDH1 gliomas produce no hyperpolarized [1- ¹³C] lactate.

• •

  Hyperpolarized [1- ¹³C] lactate is not reduced by treatment in mutant IDH1 tumors.

• •

  Mutant IDH1 gliomas present an unusual metabolic imaging profile.